SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate GEP-44. The studies, to be conducted with LabCorp, are designed to support future Phase I clinical trials by assessing safety, dosing parameters, and biomarkers across multiple species. GEP-44 is a GLP-1 agonist peptide targeting Type II diabetes and obesity, two large and growing global health markets.
The company also outlined expanded investor outreach initiatives, including a strategic agreement with Investor Brand Network (IBN) to leverage its syndication network of more than 5,000 media outlets. Additional marketing engagements and early-stage discussions to potentially acquire or license intellectual property related to ibogaine-based therapies are also underway. These efforts are intended to strengthen market awareness while supporting continued advancement of SureNano's therapeutic pipeline.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The company has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential non-injectable delivery. The initial business of SureNano Science Ltd. involves the sale and distribution of the SureNano(TM) surfactant, a ready-to-mix food grade compound for high performance nanoemulsions. The company has an exclusive license to distribute the surfactant within Canada, Oklahoma, and Colorado. SureNano is now transitioning into a pharmaceutical-focused company through the advancement of GEP-44.
The initiation of IND-enabling studies marks a critical step toward clinical development. Successful completion could pave the way for Phase I trials, potentially bringing a new treatment option for obesity and diabetes. The expanded investor outreach, including the agreement with IBN, aims to increase visibility among investors and the broader financial community. For more information, the latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF. The full press release can be viewed at https://ibn.fm/a6nGj.
These developments underscore SureNano's commitment to advancing its pipeline and engaging with the investment community. The outcome of the IND-enabling studies will be closely watched by stakeholders in the biotech and pharmaceutical sectors.
